We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+25.75%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.5B
AUM Growth
+$474M
Cap. Flow
+$174M
Cap. Flow %
4.97%
Top 10 Hldgs %
60.94%
Holding
54
New
11
Increased
8
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$94.1M
2
IRON icon
Disc Medicine
IRON
+$93.1M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$85.6M
4
VOR icon
Vor Biopharma
VOR
+$80M
5
IMVT icon
Immunovant
IMVT
+$72.4M

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$87.5M
2
ABVX
Abivax
ABVX
+$74.6M
3
EYPT icon
EyePoint Inc
EYPT
+$65.3M
4
GPCR icon
Structure Therapeutics
GPCR
+$53.4M
5
LQDA icon
Liquidia Corp
LQDA
+$48.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPSC icon
26
Century Therapeutics
IPSC
$367M
$39M 1.12%
+17,754,430
New +$37.3M
TECX
27
Tectonic Therapeutic
TECX
$696M
$37.2M 1.07%
+1,204,891
New +$29.7M
CATX icon
28
Perspective Therapeutics
CATX
$355M
$33M 0.94%
+7,915,567
New +$33.4M
XNCR icon
29
Xencor
XNCR
$1.94B
$29.6M 0.85%
2,452,138
– –
TRDA icon
30
Entrada Therapeutics
TRDA
$273M
$28.9M 0.83%
2,287,500
+199,108
+10% +$2.28M
ALXO icon
31
ALX Oncology
ALXO
$277M
$26.1M 0.75%
+13,011,849
New +$24.8M
ARVN icon
32
Arvinas
ARVN
$600M
$25.3M 0.72%
2,387,461
-278,755
-10% -$3.45M
JANX icon
33
Janux Therapeutics
JANX
$1.1B
$24.9M 0.71%
1,789,617
– –
AGMB
34
AgomAb Therapeutics NV
AGMB
$682M
$21.5M 0.62%
+2,053,233
New +$29.1M
ALEC icon
35
Alector
ALEC
$261M
$21.5M 0.62%
10,000,000
– –
MBX
36
MBX Biosciences
MBX
$3.03B
$19.4M 0.56%
650,000
– –
SLN
37
Silence Therapeutics
SLN
$834M
$16M 0.46%
3,033,560
– –
LQDA icon
38
Liquidia Corp
LQDA
$6.06B
$15.2M 0.44%
403,048
-1,307,036
-76% -$48.5M
OCUL icon
39
Ocular Therapeutix
OCUL
$2.28B
$14M 0.4%
1,647,752
-4,092,479
-71% -$39M
AVTX icon
40
Avalo Therapeutics
AVTX
$1.05B
$11M 0.32%
738,383
+255,383
+53% +$3.99M
URGN icon
41
UroGen Pharma
URGN
$2.13B
$7.29M 0.21%
405,365
-311,982
-43% -$6.25M
MNPR icon
42
Monopar Therapeutics
MNPR
$751M
$7.24M 0.21%
132,103
-9,812
-7% -$593K
CNTX icon
43
Context Therapeutics
CNTX
$35.3M
$7.03M 0.2%
+2,682,696
New +$6.26M
GPCR icon
44
Structure Therapeutics
GPCR
$3.38B
$6.77M 0.19%
140,411
-780,446
-85% -$53.4M
CGEM icon
45
Cullinan Oncology
CGEM
$1.4B
$5.78M 0.17%
+406,786
New +$5.23M
KRRO icon
46
Korro Bio
KRRO
$190M
$4.71M 0.13%
416,301
– –
LONA
47
LeonaBio Inc
LONA
$74.8M
$4.67M 0.13%
464,398
– –
UPB
48
Upstream Bio Inc
UPB
$366M
$1.63M 0.05%
181,063
-562,823
-76% -$10.1M
VTGN icon
49
VistaGen Therapeutics
VTGN
$11.2M
$1.53M 0.04%
2,676,580
– –
AGIO icon
50
Agios Pharmaceuticals
AGIO
$1.99B
– –
-1,181,841
Closed -$32.2M
1
2
3

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q1 2026 Portfolio in Review

As of Q1 2026, TCG Crossover Management held 54 positions worth $3.5B, up 16% from $3.02B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

TCG Crossover Management deployed $174M of net new capital in Q1 2026, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Disc Medicine: 1,341,862 shares worth $85.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Abivax, an estimated $74.6M trimmed.

  • TCG Crossover Management's largest Q1 2026 buy was Disc Medicine: 1,341,862 shares worth $85.8M.
  • TCG Crossover Management added most to Mirum Pharmaceuticals in Q1 2026, an estimated $94.1M increase.
  • TCG Crossover Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $74.6M.
  • TCG Crossover Management fully exited RAPT Therapeutics in Q1 2026, selling an estimated $87.5M.
  • TCG Crossover Management's ten largest holdings make up 61% of its $3.5B portfolio in Q1 2026.
  • TCG Crossover Management opened 11 new positions and closed 5 in Q1 2026.
  • TCG Crossover Management's portfolio value rose 16% quarter-over-quarter to $3.5B.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.